natalizumab IBD
Selected indexed studies
- Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials. (Gastroenterology, 2022) [PMID:34757139]
- Treatment Options for the Comorbidity of Multiple Sclerosis with Other Chronic Inflammatory Diseases. (Dtsch Arztebl Int, 2025) [PMID:40526577]
- IBD medications during pregnancy and lactation. (Nat Rev Gastroenterol Hepatol, 2014) [PMID:23897285]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials. (2022) pubmed
- Biologic agents for IBD: practical insights. (2015) pubmed
- Treatment Options for the Comorbidity of Multiple Sclerosis with Other Chronic Inflammatory Diseases. (2025) pubmed
- IBD medications during pregnancy and lactation. (2014) pubmed
- Systematic Review With Meta-Analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Diseases. (2026) pubmed
- Real World Experience With Natalizumab at a Tertiary Care Pediatric IBD Center. (2016) pubmed
- Natalizumab for induction of remission in Crohn's disease. (2018) pubmed
- Anti-integrin therapy for inflammatory bowel disease. (2018) pubmed
- New drugs on the horizon for IBD. (2014) pubmed
- Natalizumab for the treatment of multiple sclerosis and Crohn's disease. (2005) pubmed